- Home
- INIO vs GEHC Comparison
INIO vs GEHC Comparison
Compare INIO & GEHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INIO | GEHC |
|---|---|---|
| Founded | N/A | 1892 |
| Country | Germany | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Computer Software: Prepackaged Software |
| Sector | Consumer Discretionary | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.0B | 27.9B |
| IPO Year | 2026 | 2022 |
Fundamental Metrics
Financial Performance| Metric | INIO | GEHC |
|---|---|---|
| Price | $24.14 | $69.70 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $88.38 |
| AVG Volume (30 Days) | 4.9M | ★ 5.4M |
| Earning Date | N/A | 04-29-2026 |
| Dividend Yield | N/A | ★ 0.24% |
| EPS Growth | N/A | ★ 4.84 |
| EPS | N/A | ★ 0.85 |
| Revenue | N/A | ★ $20,625,000,000.00 |
| Revenue This Year | N/A | $7.12 |
| Revenue Next Year | N/A | $4.45 |
| P/E Ratio | ★ N/A | $84.59 |
| Revenue Growth | N/A | ★ 4.84 |
| 52 Week Low | $21.69 | $58.75 |
| 52 Week High | $42.95 | $89.77 |
Technical Indicators
Market Signals| Indicator | INIO | GEHC |
|---|---|---|
| Relative Strength Index (RSI) | 21.18 | 69.38 |
| Support Level | N/A | $69.17 |
| Resistance Level | $30.84 | $74.73 |
| Average True Range (ATR) | 2.92 | 2.15 |
| MACD | -0.46 | 0.51 |
| Stochastic Oscillator | 0.65 | 98.82 |
Price Performance
Historical ComparisonAbout GEHC GE HealthCare Technologies Inc.
GE HealthCare Technologies is a leading medical technology firm with leading market share in imaging and ultrasound equipment. The company reports four major segments: imaging (45% of revenue), advanced visualization solutions (26%), patient care solutions (15%), and pharmaceutical diagnostics (14%). The company's sales are geographically diverse, with the United States, EMEA, China, and the rest of the world accounting for 46%, 26%, 11%, and 17%, respectively. We estimate approximately half of its revenue is recurring, which consists of servicing (about one-third of revenue), pharmaceutical diagnostics (about 10%-15%), and digital solutions (just over 5%).